The 4DMedical Ltd (ASX: 4DX) share price is shooting higher today following the rollout of the company’s respiratory imaging platform.
At the time of writing, 4DMedical shares are swapping hands for $1.43, up 19.17%.
4DMedical makes strides on XV LVAS
In today’s statement, 4DMedical advised it has partnered with I-MED Radiology Network (I-MED) for the commercial rollout of its XV Lung Ventilation Analysis Software (XV LVAS).
I-MED is Australia’s largest diagnostic imaging provider with more than 250 clinics across the country.
The first XV LVAS deployment will occur next month at the Berwick clinic in Melbourne after a successful pilot program. Clinicians and specialists based in and around the Casey region of Victoria, Australia, will soon be able to refer patients to I-MED’s state-of-the-art Berwick imaging clinic.
4DMedical’s proprietary XV LVAS technology converts X-ray images into a four-dimensional data package using mathematical models and algorithms. The platform then provides physicians with information about a patient’s lung motion and airflow. This enables the detection and monitoring of various lung diseases which can be managed or treated if possible.
The XV LVAS is expected to be further installed within hospitals and imaging centres, offering greater accessibility for all patients. This includes sites in Brisbane and Wagga Wagga in early 2022 and at selected locations across I-MED’s network thereafter.
In addition, all facilities with XV LVAS will be able to offer 4DMedical’s lung report for both inpatient and outpatient care. This in turn is expected to maximise the number of addressable patients for the company, effectively increasing revenue streams.
4DMedical is making progress with its commercial pilots in the United States. The company currently has a near-term commercialisation pipeline, particularly within the large and important Veterans Health Administration (VHA) healthcare system.
The respiratory diagnosis industry is worth an estimated US$31 billion per annum worldwide. The United States, the world’s largest healthcare market, represents an annual opportunity of US$13.7 billion.
About the 4DMedical share price
Despite today’s gain, 4DMedical shares have disappointed investors, with the company’s share price losing 40% over the last 12 months. The company’s share price hit a 6-month low of $1.16 yesterday before rebounding higher.
4DMedical has a market capitalisation of roughly $292 million, with more than 208.95 million shares outstanding.
The post 4DMedical (ASX:4DX) share price launches 19% on first commercial scans appeared first on The Motley Fool Australia.
Should you invest $1,000 in 4DMedical right now?
Before you consider 4DMedical, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and 4DMedical wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
- Life360 (ASX:360) share price halted amid $280 million acquisition
- Why ASIC chair warns ‘great caution’ needed when investing in crypto
- Does the lower Zip Co (ASX:Z1P) share price make it a takeover target?
- Kogan shares or Temple & Webster? This expert has their say
- Are Webjet (ASX:WEB) shares still worth buying with travel opening up?
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/32q1mOy